Support for the
ABILIFY MYCITE® System

These resources are designed to support you
and your patients throughout your experience
with the ABILIFY MYCITE System.

Talk to an Otsuka
representative

Want to learn more about the ABILIFY MYCITE System? Healthcare professionals can request to speak with an Otsuka representative who can help provide answers.

Request

Please enter the following information. 
All fields are mandatory.

I would like to request information from (select all that apply):

By clicking "SUBMIT" below, you agree to be contacted by phone or email regarding your request.
Downloadable resources

Download these materials for
your practice.

Healthcare Provider Pre‑registration Form

Prescription Form

Talking to Your Patients About the ABILIFY MYCITE System Brochure

Setup Appointment Email Template

The MYCITE® Team       

Questions? Call the MYCITE Team for more information at 844‑MYCITE‑3 (844‑692‑4833). We are available 8 AM to midnight eastern time, 7 days per week.

The MYCITE Team can help patients and your office staff with:

Setting Up The ABILIFY MYCITE® System, Icon

Setting up the ABILIFY MYCITE System

ABILIFY MYCITE® System Questions & Technical Support, Icon

Questions and technical support

Contacting the Specialty Pharmacy, Icon

Contacting the specialty pharmacy regarding a patient’s prescription and refills

Begin your
registration now.

ENROLL YOUR PRACTICE

ABILIFY MYCITE® System Registration

Support for your patients

Self-check tool

The self-check tool is designed to help patients determine if the ABILIFY MYCITE System might be for them. Patients are encouraged to bring in the self-check tool to help facilitate the conversation.

See the tool

Downloadable resources

The resources below are designed to educate and answer questions your patients might have about the system.

Meet the ABILIFY MYCITE System Brochure

Getting started with the ABILIFY MYCITE System Brochure

Frequently asked questions

Starting your patients on
the ABILIFY MYCITE System

Who can prescribe an
ABILIFY MYCITE® Kit?

In most cases, an ABILIFY MYCITE Kit can be prescribed by a psychiatrist, psychiatric nurse, or primary care physician.

Is the ABILIFY MYCITE System
available to my patients?

The system is covered under many insurance plans. 
Find more information here.

Who is the ABILIFY MYCITE System for?

ABILIFY MYCITE® (aripiprazole tablets with sensor) 
is a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion.
It is indicated in adults for the:

  • Treatment of schizophrenia
  • Treatment of bipolar I disorder as monotherapy and as adjunct to lithium or valproate for:
    • Acute treatment of manic and mixed episodes
    • Maintenance treatment
  • Adjunctive treatment of major depressive disorder

Limitations of Use: ABILIFY MYCITE has not been shown to improve patient compliance or for use in modifying aripiprazole dosage. It should not be used in “real-time” or during an emergency, because detection may be delayed or not occur.

What adverse reactions are associated
with the MYCITE® Patch?

Symptoms of skin irritation localized at the site of the MYCITE® Patch may occur in some patients. In clinical studies of 492 patients, 61 (12.4%) experienced skin rashes localized at the site of patch placement. No serious adverse reactions related to the ingestible sensor were reported in clinical studies.

These are not all the adverse reactions associated with the ABILIFY MYCITE System. The safety of ABILIFY MYCITE for the treatment of adults with schizophrenia, treatment of adults with manic and mixed episodes associated with bipolar I disorder, and adjunctive treatment of adults with major depressive disorder (MDD) has been established and is based on trials of aripiprazole.

What is the most important information about the medication in ABILIFY MYCITE tablets?

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (1.6 to 1.7 times) compared to placebo-treated patients. ABILIFY MYCITE is not approved for the treatment of patients with dementia-related psychosis.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults. Those on antidepressant therapy should be monitored closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. The safety and effectiveness of ABILIFY MYCITE have not been established in pediatric patients.

What are the most commonly observed adverse reactions of ABILIFY MYCITE tablets?

The most common adverse reactions seen in ≥5% of adult patients (and at least twice that for placebo) were: schizophrenia: akathisia; bipolar mania (monotherapy): akathisia, sedation, restlessness, tremor, and extrapyramidal disorder; bipolar mania (adjunctive therapy with lithium or valproate): akathisia, insomnia, and extrapyramidal disorder; and major depressive disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision.

About the components

My office is planning to start a patient on the ABILIFY MYCITE System. What can we expect to receive in the ABILIFY MYCITE® Kit?

The ABILIFY MYCITE Kit includes a 30-day supply of ABILIFY MYCITE® (aripiprazole tablets with sensor) Pills, 7 MYCITE® Patches, and instructions on how to set up the system with the MYCITE® App. If the patient has any questions, they can call the MYCITE Team at 844-MYCITE-4 (844-692-4834).

What is the ABILIFY MYCITE Pill made of?

Each aripiprazole pill is directly embedded at the point of manufacture with an Ingestible Event Marker (IEM) sensor that is the size of a grain of sand or about 1 mm. After a pill is digested, the sensor is excreted from the body.1

Is there any medication in the MYCITE Patch?

No. The patch is not medicated.

Can patients with a latex allergy use the MYCITE Patch?

All MYCITE Patch materials that contact the skin have been tested and meet appropriate biocompatibility standards. The patch adhesive area consists of hydrogels, hydrocolloids, and acrylic—it does not contain latex. The remainder of the patch also does not contain latex, but it cannot be verified or labeled as latex-free.

Technical questions

My patient is having trouble setting up the ABILIFY MYCITE System. Who can help?

If a patient has any questions about setting up the ABILIFY MYCITE System, the MYCITE Team will be ready to help them at 844-MYCITE-4 (844-692-4834).

My patient is having trouble setting up the
ABILIFY MYCITE System. Who can help?

If a patient has any questions about setting up the ABILIFY MYCITE System, the MYCITE Team will be ready to help them at 844-MYCITE-4 (844-692-4834).

I am having trouble with the MYCITE® Dashboard or need technical assistance. Who can help?

The MYCITE Team is here to provide you and your office staff with any support you may need with the ABILIFY MYCITE System. Call the MYCITE Team for more information at 844-MYCITE-3 (844-692-4833).

I am having trouble with the MYCITE® Dashboard
or need technical assistance. Who can help?

The MYCITE Team is here to provide you and your office staff with any support you may need with the ABILIFY MYCITE System. Call the MYCITE Team for more information at 844-MYCITE-3 (844-692-4833).

How long does it take for the signal to go
from the sensor to the MYCITE® App?

The ABILIFY MYCITE System is intended to track if the ABILIFY MYCITE® (aripiprozole tablets with sensor) Pill has been taken. Approximately 94% of all ingestions are registered by the MYCITE® Patch within 3 minutes after ingestion. However, it may take up to 2 hours for the MYCITE App and MYCITE® Dashboard to detect an ingestion. In some cases, ingestion of a tablet may not be detected; if a tablet is not detected after ingestion, the dose should not be repeated.2

Some factors, such as connectivity, transmitter malfunction, or device availability may impact the consistency and reliability of data detection, collection, and transmission.

How close does the patient need to be to
his or her smartphone?

The MYCITE® Patch records ingestion of the tablet and other physiological data. It will connect with the MYCITE App once it is within Bluetooth®* range, which is approximately 9 feet. Your patient will need to have access to a regular and reliable internet connection to be able to use the ABILIFY MYCITE System.

*Bluetooth is a registered trademark of Bluetooth SIG, Inc.

Is the MYCITE App available for all
smartphones and operating systems?

The MYCITE App is compatible with most of the following devices and operating systems:

  • Apple iPhone®: iPhone 6S (or higher) with iOS® 10.x (or higher)
  • Android™: Samsung Galaxy™ S7/S8, Google Pixel™ 2 (or higher) with Android Nougat-7 (or higher)

It is advised that patients check their smartphones’ app store or call the MYCITE Team at 844‑MYCITE‑4 (844‑692‑4834) to ensure compatibility with their specific smartphones and operating systems. If patients don't see their device, but it still meets the operating system requirements listed above, they will still likely be able to use the MYCITE App. The MYCITE App is designed to be identical across Android and iOS except where differences are required by the respective operating systems.

iPhone and iOS are registered trademarks of Apple, Inc.
"Samsung" and "Galaxy" are trademarks of Samsung in the United States or other countries.
"Google," "Android," and "Pixel" are trademarks of Google, LLC.

Does the ABILIFY MYCITE System work if a patient is traveling outside of the country?

The ABILIFY MYCITE System will still work outside the country. Data plan and roaming charges may apply based on the patient’s phone plan and WiFi connection.

When traveling by airplane within or outside of the country, the patient should consider requesting a medical waiver to indicate why they are wearing a patch. Additionally, when going through airport security, the patient may request a pat-down instead of having to go through the body scanner.

Privacy

Who can view patient information?

How patients share their data is up to them. Patients can share the daily data in their app with you and other members of their care team. They can also choose to share all or some of their data with anyone else they would want to know—like close family members or friends.1 

Patients can stop sharing information at any time, and data are encrypted and stored securely in the cloud, ensuring patient privacy. Keep in mind that you will be able to view your patients' data as long as they continue to share with you and use the system.

For more information on how you and your patients' information will be used, please read the ABILIFY MYCITE® System Terms of Use, Privacy Notice, and Authorization & Consent.

Could the ABILIFY MYCITE System be used to track
the location of the individual?

No. There is no geolocation functionality associated with any element of the ABILIFY MYCITE System.

Could the ABILIFY MYCITE System be used to track the location of the individual?

No. There is no geolocation functionality associated with any element of the ABILIFY MYCITE System.

Why do I have to give out my email address on the Pre‑registration Form?

Your patients will use your email address to invite you to connect within the ABILIFY MYCITE System. If you would rather not share your usual email address, you might consider setting up a secure separate email account specifically for the ABILIFY MYCITE System. It is important to explain to your patients that they should not use the email address to communicate with you. You will be able to provide your patient your email address during the office setup appointment.

Discover how the ABILIFY MYCITE System can provide data-driven insights to help inform treatment decisions.

LEARN MORE

ABILIFY MYCITE® System Components

References

1. Otsuka and Proteus® announce the first U.S. FDA approval of a digital medicine system: ABILIFY MYCITE® (aripiprazole tablets with sensor) [press release]. Tokyo, Japan, and Redwood City, CA; November 14, 2017. https://www.otsuka-us.com/discover/articles-1075. Accessed September 19, 2019. 2. Profit D, Rohatagi S, Zhao C, Hatch A, Docherty JP, Peters-Strickland TS. Developing a digital medicine system in psychiatry: ingestion detection rate and latency period. J Clin Psychiatry. 2016;77(9):e1095-e1100.